| 摘要 |
<p><P>PROBLEM TO BE SOLVED: To provide a new ophthalmic medicine specified for the subconjunctival administration effective for the suppression of a rejection in a local transplantation in eye, glaucoma and the suppression of eye allergy inflammation. <P>SOLUTION: This ophthalmic medicine consists of a compound containing at least 1 kind selected from the group consisting of N,N'-diacylcystine and its esters. The medicine suppresses the rejection of an allo transplanting piece considered as a Th1 response of a cellular immunity, and the eye allergy and eye inflammation considered to be a Th2 response. <P>COPYRIGHT: (C)2005,JPO&NCIPI</p> |
